Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer

Pharmacotherapy

Volumn 28, Issue 6, 2008, Pages 742-754

  Jean, Gary W ^a   Shah, Sachin R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adverse events; Cetuximab; EGFR; Epidermal growth factor receptor; Metastatic colorectal cancer; Monoclonal antibodies; Panitumumab

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MEMBRANE PROTEIN; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; CANCER INVASION; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EYE IRRITATION; EYE TOXICITY; EYELID DISEASE; FATIGUE; HUMAN; HYPEREMIA; HYPERSENSITIVITY REACTION; HYPOMAGNESEMIA; INTERSTITIAL LUNG DISEASE; LACRIMATION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG FIBROSIS; LUNG TOXICITY; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; NAUSEA; PARONYCHIA; PROTEIN EXPRESSION; RASH; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 47149084688     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.6.742     Document Type: Review

References (56)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.
2. De Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol (2005 ASCO annual meeting proceedings) 2005;23(16S, June 1 suppl):3501.
3. American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer Society; 2006.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Saltz LB, Douilard JY, Pirotta N, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6:81-91.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
7. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37-46.
8. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006;107:1207-18.
9. Reynolds NA, Wagstaff AJ. Cetuximab in the treatment of metastatic colorectal cancer. Drugs 2004;64:109-18.
10. Diasio RB, Fourie J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs 2006;66:1441-63.
11. Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006;66:2005-16.
12. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13.
13. Amgen. Vectibix (panitumumab) package insert. Thousand Oaks, CA; 2006.
14. ImClone Systems Incorporated, Bristol-Myers Squibb. Erbitux (cetuximab) package insert. New York, NY, and Princeton, NJ; 2006.
15. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-33.
16. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody c225. Clin Cancer Res 1999;5:909-16.
17. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
18. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
19. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002;13:609-14.
20. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-15.
21. Pfeiffer P, Bjerregaard JK, Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab administration: double dose every second week as a 60 minute infusion [abstract]. J Clin Oncol (2007 ASCO annual meeting proceedings) 2007;25(18S, June 20 suppl):4133.
22. Cervantes A, Ciardiello F, Rivera F, et al. Optimal dose of cetuximab administered every 2 weeks (q2w): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. In: Program and proceedings of the 2007 annual meeting of the American Association for Cancer Research. Philadelphia, PA: American Association for Cancer Research, 2007:LB-352.
23. Ettlinger DE, Mitterhauser M, Wadsak W, et al. In vivo disposition of irinotecan (cpt-11) and its metabolites in combination with the monoclonal antibody cetuximab. Anticancer Res 2006;26:1337-42.
24. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:427-32.
25. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal caner. N Engl J Med 2004;351:337-45.
26. Sobrero AF, Fehrenbacher L, Rivera F, et al. Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial [abstract]. In: Program and proceedings of the 2007 annual meeting of the American Association for Cancer Research. Philadelphia, PA: American Association for Cancer Research, 2007:LB-2.
27. Jonker DJ, Karapetis CS, Moore M, et al. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG) [abstract]. In: Program and proceedings of the 2007 annual meeting of the American Association for Cancer Research. Philadelphia, PA: American Association for Cancer Research, 2007:LB-1.
28. Vincenzi B, Santini D, Rabitti C, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 2006;94:792-7.
29. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
30. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
31. Wilke H, Glynne-Jones R, Thaler J, et al. MABEL: a large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer [abstract]. J Clin Oncol (2006 ASCO annual meeting proceedings) 2006;24(18S suppl):3549.
32. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
33. Smith DM, Legoux J, Brunet R, et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in second and third line treatment of metastatic colorectal cancer (mCRC): safety and efficacy analysis [abstract]. J Clin Oncol (2006 ASCO annual meeting proceedings) 2006;24(18S, June 20 suppl):3558.
34. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-61.
35. Jennis A, Polikoff J, Mitchell E, et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial [abstract]. J Clin Oncol (2005 ASCO annual meeting proceedings) 2005;23(16S, June 1 suppl):3574.
36. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/LA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract]. J Clin Oncol (2007 ASCO annual meeting proceedings) 2007;25(18S, June 20 suppl):4000.
37. Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen [press release]. Thousand Oaks, CA: Amgen; March 22, 2007. Available from www.amgen.com. Accessed March 22, 2007.
38. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the gruppo oncologico dell'Italia meridionale. J Clin Oncol 2005;23:4866-75.
39. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest. J Clin Oncol 2007;25:1670-6.
40. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the hellenic oncology research group (HORG). Br J Cancer 2006;94:798-805.
41. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 2007;25:1539-44.
42. Folprecht G, Lutz MP, Schoffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-6.
43. Heinemann V, Moosmann N, Vehling-Kaiser U, et al. XELIRI plus cetuximab versus XELOX plus cetuximab for first-line therapy of metastatic colorectal cancer (CRC): a randomized trial of the AIO CRC study group [abstract]. J Clin Oncol (2007 GI-ASCO annual meeting proceedings) 2007:abstract 278.
44. Ocean AJ, O'Brien K, Lee J, et al. Phase II trial of FOLFOX6, becacizumab and cetuximab in patients with colorectal cancer [abstract]. J Clin Oncol (2007 ASCO annual meeting proceedings) 2007;25(18S, June 20 suppl):4075.
45. ClinicalTrials.gov. Clinical trials 2007. Available from www.clinicaltrials.gov. Accessed July 7, 2007.
46. Cancer and Leukemia Group B, Southwest Oncology Group. CALGB/SWOG 80405: a phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum. Clin Adv Hematol Oncol 2006;4:452-3.
47. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010-17.
48. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunochemistry. J Clin Oncol 2005;23:1803-10.
49. Vincenzi B, Santini D, Tonini G. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor [letter]. J Clin Oncol 2006;24:1957.
50. Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials [abstract]. J Clin Oncol (2007 ASCO annual meeting proceedings) 2007;25(18S, June 20 suppl):4134.
51. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97:1221-4.
52. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23:165-74.
53. Carson EJ, Novak AM, Stella PJ. Hypomagnesemia in patients with stage IV colorectal cancer treated with cetuximab as a single agent [abstract]. J Clin Oncol (2005 ASCO annual meeting proceedings) 2005;23(16S, June 1 suppl):3655.
54. Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006;6:152-6.
55. Abubakr Y, Eng C, Pautret V, et al. Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of 800 patients in a randomized phase III trial (EPIC) [abstract]. J Clin Oncol (2006 ASCO annual meeting proceedings) 2006;24(18S):3556.
56. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007;6:529-31.